Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include MicroRNA in disease regulation, Cancer-related molecular mechanisms research, RNA modifications and cancer, and Extracellular vesicles in disease.
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
WWP1–SHARP1–C/EBPβ positive feedback loop modulates development of metabolic dysfunction–associated steatotic liver disease
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
<scp>TRIM8</scp> promotes ovarian cancer proliferation and migration by targeting <scp>VDAC2</scp> for ubiquitination and degradation
Development of anti-cancer drugs for tumor-associated macrophages: a comprehensive review and mechanistic insights
miR-20b-5p exerts protective effects against experimental autoimmune encephalomyelitis in mice by inhibiting NLRP3 transcription and NLRP3/ASC/caspase-1 axis activation
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Not Only in Sensorimotor Network: Local and Distant Cerebral Inherent Activity of Chronic Ankle Instability—A Resting-State fMRI Study
Glycopattern Alteration of Glycoproteins in Gastrointestinal Cancer Cell Lines and Their Cell-Derived Exosomes
Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study
Abstract P5-18-06: Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.
Norepinephrine‐CREB1‐miR‐373 axis promotes progression of colon cancer
<p>Low-Temperature Plasma Suppresses Proliferation and Induces Apoptosis in Lung Cancer Cells by Regulating the miR-203a/BIRC5 Axis</p>
miR‐22 and miR‐214 targeting BCL9L inhibit proliferation, metastasis, and epithelial‐mesenchymal transition by down‐regulating Wnt signaling in colon cancer
A new three‐dimensional glass scaffold increases the in vitro maturation efficiency of buffalo (<i>Bubalus bubalis</i>) oocyte via remodelling the extracellular matrix and cell connection of cumulus cells
Extracellular Vesicle-Associated mir-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma
MicroRNA-214 targets Wnt3a to suppress liver cancer cell proliferation
Genomic variations of the mevalonate pathway in porokeratosis